Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Completed · Phase 1
Conditions studied: Recurrent Melanoma, Stage IV Melanoma
In brief
RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma.
Key facts
- Study ID
- NCT01103635
- Run by
- Abramson Cancer Center at Penn Medicine
- People needed
- 25
- Starts
- 2010-02-01
- Expected to finish
- 2016-05-02
- Last updated by the study team
- 2020-04-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.